Diols

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Retrieved on: 
Monday, July 26, 2021
Chemical compounds, Chemistry, Cyclopropanes, Diols, Irofulven, Ketones

Hrsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) Allarity Therapeutics A/S (Allarity) and Lantern Pharma Inc. (Lantern) today announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full authority to manage and guide future clinical development and commercialization.

Key Points: 
  • Hrsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) Allarity Therapeutics A/S (Allarity) and Lantern Pharma Inc. (Lantern) today announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full authority to manage and guide future clinical development and commercialization.
  • The drug was originally developed by MGI Pharma (USA) and Eisai (Japan), through Phase 3 clinical trials.
  • Under the agreement, Lantern will purchase assets and reacquire global, exclusive rights to further develop and commercialize Irofulven, and Allarity will discontinue further involvement in the Irofulven program.
  • Lantern will also receive a license to utilize, in its sole discretion, Allaritys Irofulven DRP companion diagnostic in future clinical development and commercialization of the drug.

RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans

Retrieved on: 
Tuesday, July 13, 2021
Drugs, Clinical medicine, Morphinans, Opioid antagonists, Psychoactive drugs, Daiichi Sankyo, Diols, Naloxegol, Abdominal pain, Opioid withdrawal, Opioid

"This important new listing as an unrestricted preferred brand strengthens Movantik's leadership position and now means that over 30 million more Americans will have access to Movantik.

Key Points: 
  • "This important new listing as an unrestricted preferred brand strengthens Movantik's leadership position and now means that over 30 million more Americans will have access to Movantik.
  • Almost 9 out of 10 U.S. commercial lives are now covered and we continue to work toward additional formulary coverage for the remaining patients."
  • Movantik (naloxegol) is contraindicated in:
    Patients with known or suspected gastrointestinal (GI) obstruction and patients at risk of recurrent obstruction, due to the potential for GI perforation.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.

Lannett Launches Fluvastatin Sodium ER Tablets

Retrieved on: 
Monday, July 12, 2021
Chemistry, Organic chemistry, Carboxylic acids, Physical sciences, Diols, Statins, Hepatotoxins, Fluvastatin, Indoles, Novartis, Tablet computer

PHILADELPHIA, July 12, 2021 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product.

Key Points: 
  • PHILADELPHIA, July 12, 2021 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product.
  • Total U.S. sales of Fluvastatin Sodium Extended-release Tablets, 80 mg, according to IQVIA market, were approximately $10 million for the 12 months ending May 2021, although actual generic market values are expected to be lower.
  • "Although the market potential is modest, we are pleased to offer an affordable Fluvastatin alternative to our customers," said Tim Crew, chief executive officer of Lannett.
  • "Currently, only one other competitor markets generic Fluvastatin Sodium Extended-release Tablets, 80 mg, in the U.S."
    Fluvastatin Sodium Extended-release Tablets, the generic equivalent of Novartis' Lescol XL Tablets, is used as an adjunct to diet to treat elevated cholesterol levels.

Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Retrieved on: 
Thursday, June 24, 2021
Glucocorticoids, Organ systems, Medicine, Medical specialties, Prodrugs, Pregnanes, Muscular dystrophy, Diols, Vamorolone, Prednisone, Dystrophy, Duchenne

The study also demonstrated superiority of both vamorolone dose levels (2 and 6mg/kg/day) versus placebo across multiple secondary endpoints.

Key Points: 
  • The study also demonstrated superiority of both vamorolone dose levels (2 and 6mg/kg/day) versus placebo across multiple secondary endpoints.
  • Vamorolone did not stunt growth, as validated in the current 24-week study, in which vamorolone 6mg/kg/day versus prednisone 0.75mg/kg/day showed a significant difference in growth velocity (p=0.02).
  • The primary endpoint of the study is TTSTAND velocity at 24 weeks comparing the 6mg/kg/day dose of vamorolone to placebo.
  • ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders.

Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation

Retrieved on: 
Wednesday, June 16, 2021
Clinical medicine, Medical specialties, Medicine, Opioid antagonists, Diols, Ethers, Ketones, Naltrexone, Phenols, Low-dose naltrexone, Opioid use disorder, Immunotherapy

In one set of experiments, interleukin-2, an FDA cleared cancer immunotherapy drug is combined with low dose naltrexone to potently reduce schizophrenic-like behavior in an animal model of the condition.

Key Points: 
  • In one set of experiments, interleukin-2, an FDA cleared cancer immunotherapy drug is combined with low dose naltrexone to potently reduce schizophrenic-like behavior in an animal model of the condition.
  • Naltrexone is a medication approved by the Food and Drug Administration (FDA) to treat both opioid use disorder and alcohol use disorder as a medication-assisted treatment option.
  • Studies also showed that low dose naltrexone synergizes with mesenchymal stem cells and myeloid suppressor cells, both cell types are capable of inducing the generation of T regulatory cells in vivo.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Global Diethylene Glycol Monobutyl Ether Industry (2020 to 2027) - Key Market Trends and Drivers - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Alcohols, Polyols, Commodity chemicals, Glycol ethers, Adulteration, Diethylene glycol, Diols, Household chemicals, Ethylene glycol, C8H18O3

The "Diethylene Glycol Monobutyl Ether - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diethylene Glycol Monobutyl Ether - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Diethylene Glycol Monobutyl Ether estimated at US$178.7 Million in the year 2020, is projected to reach a revised size of US$232.9 Million by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $48.3 Million, While China is Forecast to Grow at 6.2% CAGR
    The Diethylene Glycol Monobutyl Ether market in the U.S. is estimated at US$48.3 Million in the year 2020.
  • In the global Other Applications segment, USA, Canada, Japan, China and Europe will drive the 3.2% CAGR estimated for this segment.

China Budesonide Market Report 2021: Sales Decreased by 29.30% in 2020 - Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 30, 2021
Health, Pharmaceutical, Steroids, Drugs, Glucocorticoids, Corticosteroids, Diketones, Diols, Pregnanes, Budesonide, Compound annual growth rate, Adrenal gland

b'The "Investigation Report on China\'s Budesonide Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%.

Key Points: 
  • b'The "Investigation Report on China\'s Budesonide Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%.
  • However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 pandemic.
  • With the improvement of the epidemic situation, the analyst predicts that the sales of Budesonide in China will have a recovery growth in the short run.\nBudesonide is an adrenal cortex hormone medicine.
  • Thus, the analyst analyzes that in addition to the recovery growth, the sales of Budesonide will increase in 2021-2025 as the market expands.\n2 Sales of Budesonide in China, 2016-2020\n2.3 Sales of Budesonide by Dosage Form in China, 2016-2020\n'

Diethylene Glycol Monoethyl Ether Market Size Is Projected to Reach $608.4 Million By 2028 | CAGR: 4.8%: Polaris Market Research

Retrieved on: 
Monday, April 19, 2021
Alcohols, Polyols, Commodity chemicals, Household chemicals, Glycol ethers, Adulteration, Diethylene glycol, Diols, Di(propylene glycol) methyl ether, Ethylene glycol, Polyethylene terephthalate

b"NEW YORK, April 19, 2021 /PRNewswire/ -- The global diethylene glycol monoethyl ether market size is expected to reach USD 608.4 million by 2028 according to a new study conducted by Polaris Market Research.

Key Points: 
  • b"NEW YORK, April 19, 2021 /PRNewswire/ -- The global diethylene glycol monoethyl ether market size is expected to reach USD 608.4 million by 2028 according to a new study conducted by Polaris Market Research.
  • the market is anticipated to Register a CAGR: 4.8% From 2021 2028.
  • Growing concerns related to cleanliness and hygiene among people across the globe have caused a surge in demand for cleaning agents, which in turn driving the market growth.
  • These key players are working in the several collaborations with oil and gas companies to ensure long term procurement of raw materials.\nTo Get Incredible Discounts On This Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/diethylene-glyco...\nPolaris Market research has segmented the diethylene glycol monoethyl ether market report on the basis of application, end-use, and region:\nDiethylene Glycol Monoethyl Ether Application Outlook (Revenue, USD Million, 2016 2028)\n"

Sodium Fusidate Oral: A Bacterial Protein Synthesis Inhibitor by Preventing the Turnover Ofelongation Factor G (EF-G) from the Ribosome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 7, 2021
Health, Pharmaceutical, Chemistry, Protein biosynthesis, Physical sciences, Branches of biology, Diols, Fusidic acid, Desiccants, Protein synthesis inhibitor, EF-G, Sodium, Elongation factor

"SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.

Key Points: 
  • "SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Sodium Fusidate oral, (also known as Fusidic acid, FA or sodium fusidate) acts as a bacterial protein synthesis inhibitor by preventing the turnover ofelongation factor G (EF-G) from the ribosome.
  • What are the other emerging products available and how these are giving competition to SODIUM FUSIDATE ORAL?

FDA Approves Althera's Roszet (rosuvastatin and ezetimibe) Tablets, a New Oral Therapy for Powerful Cholesterol Reduction

Retrieved on: 
Wednesday, March 31, 2021
Drugs, Chemical compounds, Chemistry, Statins, Carboxylic acids, Diols, Hepatotoxins, Cholesterol absorption inhibitor, Rosuvastatin, Ezetimibe, Low-density lipoprotein, Cholesterol

Roszet contains rosuvastatin, a powerful statin for LDL-C reduction, and ezetimibe, an efficacious cholesterol absorption inhibitor.

Key Points: 
  • Roszet contains rosuvastatin, a powerful statin for LDL-C reduction, and ezetimibe, an efficacious cholesterol absorption inhibitor.
  • Rosuvastatin and ezetimibe have been extensively studied in combination therapy and have been shown to significantly reduce LDL cholesterol beyond the statin alone.
  • Combination therapy has been widely used in hypertension to achieve lower blood pressure targets.
  • Althera is continuing to work with all stakeholders to ensure that Roszet is affordable and accessible to all.